The Phase 1 trial is expected to enrol 60 volunteers in the United States with no history of malaria to evaluate the vaccine candidate at three dose levels, BioNTech said in a statement.
The company said it will initially evaluate different antigens of the parasite that causes malaria over the coming months to help select the multi-antigen vaccine candidate with which to proceed to later-stage trials.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
BioNTech initiates clinical trial of mRNA-based malaria vaccine candidate - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.BioNTech has initiated a first-in-human Phase 1 clinical trial of its BNT165b1 malaria vaccine candidate using mRNA technology, the German company announced on Friday. Looks like mRNA is gaining more traction after the success that Moderna labs had From our experience with covid mRNA 'vaccines' I would advise people to stay away from this 'technology', but it is a matter of free choice I guess.
Source: SABCNews - 🏆 37. / 51 Read more »
BioNTech starts human trials on a vaccine for malariaThe company’s planned vaccine production site in Kigali, Rwanda will help produce the malaria shot
Source: BDliveSA - 🏆 12. / 63 Read more »
BioNTech ships 11 500 doses of COVID vaccine to China - SABC News - Breaking news, special reports, world, business, sport coverage of all South African current events. Africa's news leader.BioNTech said on Thursday it had shipped 11 500 doses of its COVID19 vaccine to China to be administered initially to German expatriates, marking the first foreign coronavirus vaccines to be sent to the country.
Source: SABCNews - 🏆 37. / 51 Read more »